Business Context and Reporting Period
Company: Achieve Life Sciences, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 13, 2019
Context: The filing discloses a corporate presentation containing data from the Phase 2b ORCA-1 Trial, scheduled for presentation at the Society for Research on Nicotine & Tobacco Europe 19th Annual Conference.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on regulatory disclosure of clinical trial data rather than financial performance.
Material Changes
No material financial changes versus prior periods are reported in this document. The primary event is the dissemination of clinical trial data via a corporate presentation (Exhibit 99.1).
Guidance, Outlook, and Risks
- Regulation FD Disclosure: The company is disclosing the corporate presentation under Item 7.01 to ensure fair disclosure of material non-public information regarding the ORCA-1 Trial.
- Legal Status of Information: The information in Item 7.01 and Exhibit 99.1 is furnished and shall not be treated as "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. It is not incorporated by reference into other filings unless expressly stated.
- Outlook: The filing implies ongoing development of the ORCA-1 program, with data presentation occurring on the filing date.
Investor Verification Checklist
- Verify the specific clinical outcomes and data points presented in the attached Exhibit 99.1 (Corporate Presentation).
- Confirm the status of the Phase 2b ORCA-1 Trial and any subsequent regulatory milestones.
- Review the company's most recent 10-Q or 10-K for actual financial metrics, as this 8-K does not contain them.